Sunday, February 11, 2018 6:21:15 PM
"Bryostatin Effects on Cognitive Function and PKC epsilon in Alzheimer’s Disease Phase IIa and Expanded Access Trials" (2017)
https://content.iospress.com/download/journal-of-alzheimers-disease/jad170161?id=journal-of-alzheimers-disease%2Fjad170161
"Protein Kinase C epsilon (PKC epsilon) Promotes Synaptogenesis through Membrane Accumulation of the Postsynaptic Density Protein PSD-95" (2016)
http://www.jbc.org/content/291/32/16462.full.pdf?with-ds=yes
"Bryostatin-1 Restores Blood Brain Barrier Integrity following Blast-Induced Traumatic Brain Injury" (2014)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000781/pdf/nihms810689.pdf
"PKC epsilon Deficits in Alzheimer’s Disease Brains and Skin Fibroblasts" (2014)
https://www.researchgate.net/profile/Daniel_Alkon-BRNI/publication/264794792_PKCe_Deficits_in_Alzheimer%27s_Disease_Brains_and_Skin_Fibroblasts/links/565daf2a08aefe619b267c7a/PKCe-Deficits-in-Alzheimers-Disease-Brains-and-Skin-Fibroblasts.pdf
"Common Mechanisms of Alzheimer’s Disease and Ischemic Stroke: The Role of Protein Kinase C in the Progression of Age-Related Neurodegeneration" (2014)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446718/pdf/nihms659711.pdf
"Fibroblast Aggregation Rate Converges with Validated Peripheral Biomarkers for Alzheimer’s Disease" (2014)
https://www.researchgate.net/profile/Daniel_Alkon-BRNI/publication/263934332_Fibroblast_Aggregation_Rate_Converges_with_Validated_Peripheral_Biomarkers_for_Alzheimer%27s_Disease/links/565db4ae08aefe619b268e9f/Fibroblast-Aggregation-Rate-Converges-with-Validated-Peripheral-Biomarkers-for-Alzheimers-Disease.pdf
"PKC epsilon Promotes HuD-Mediated Neprilysin mRNA Stability and Enhances Neprilysin-Induced Ab Degradation in Brain Neurons" (2014)
http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0097756&type=printable
"Bryostatin-1 Restores Hippocampal Synapses and Spatial Learning and Memory in Adult Fragile X Mice" (2014)
http://jpet.aspetjournals.org/content/jpet/349/3/393.full.pdf
"Spatiotemporal Complexity of Fibroblast Networks Screens for Alzheimer’s Disease" (2012)
https://www.researchgate.net/profile/Florin_Chirila/publication/230657221_Spatiotemporal_Complexity_of_Fibroblast_Networks_Screens_for_Alzheimer%27s_Disease/links/5757144408ae5c65490423ee/Spatiotemporal-Complexity-of-Fibroblast-Networks-Screens-for-Alzheimers-Disease.pdf
"Apolipoprotein E3 (ApoE3) but Not ApoE4 Protects against Synaptic Loss through Increased Expression of Protein Kinase C epsilon" (2012)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346146/pdf/zbc15947.pdf
"PKC epsilon Activation Prevents Synaptic Loss, Ab Elevation, and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice" (2011)
http://www.jneurosci.org/content/jneuro/31/2/630.full.pdf
"Postischemic PKC activation rescues retrograde and anterograde long-term memory" (2009)
http://www.pnas.org/content/pnas/106/34/14676.full.pdf
"Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains" (2008)
http://www.pnas.org/content/pnas/105/36/13620.full.pdf
"A structural basis for enhancement of long-term associative memory in single dendritic spines regulated by PKC" (2007)
http://www.pnas.org/content/pnas/104/49/19571.full.pdf
"Bryostatin Enhancement of Memory in Hermissenda" (2006)
http://www.journals.uchicago.edu/doi/pdfplus/10.2307/4134558
"Protein synthesis required for long-term memory is induced by PKC activation on days before associative learning" (2005)
http://www.pnas.org/content/pnas/102/45/16432.full.pdf
"Therapeutic effects of PKC activators in Alzheimer’s disease transgenic mice" (2004)
http://www.pnas.org/content/pnas/101/30/11141.full.pdf
Recent SNPX News
- Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics • PR Newswire (US) • 04/09/2024 01:15:00 PM
- Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 04/03/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:16:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:18 PM
- Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders • PR Newswire (US) • 12/19/2023 02:00:00 PM
- Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's • PR Newswire (US) • 12/06/2023 02:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/14/2023 10:05:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/13/2023 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 10:00:23 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/03/2023 09:00:19 PM
- Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology • PR Newswire (US) • 11/02/2023 01:00:00 PM
- Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease • PR Newswire (US) • 09/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:05:55 PM
- Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study • PR Newswire (US) • 09/07/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:00:40 PM
- Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 07/19/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2023 12:55:57 PM
- Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience • PR Newswire (US) • 07/13/2023 01:00:00 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM